Needle‐free cervical cancer treatment using helical multishield intracavitary rotating shield brachytherapy with the ¹⁶⁹Yb Isotope

Abstract

¹⁶⁹ Yb-based RSBT for cervical cancer met the HR-CTV D₉₀ goal of 85 Gy in a greater percentage of the patients considered than IC/IS (86% vs 84%, respectively) and can reduce overall treatment time relative to IC/IS. ¹⁶⁹ Yb-based RSBT could be used to replace IC/IS in instances where IC/IS treatment is not available, especially in instances when HR-CTV volumes are ≥30 cm³ .